PRQR ProQR Therapeutics N.V.
Price Chart
Executive Summary
ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of shareholders held on June 2, 2026. All agenda items were approved, including adoption of 2025 annual accounts, appointment of a new non-executive director, re-appointment of KPMG as auditor, amendment of articles to increase authorized capital, and authorization for the board to issue and repurchase shares. The board committees were also reconstituted. This is a routine governance filing with no material financial or operational news.
Actionable Insight
This filing contains no material financial or operational data — it is a routine annual meeting report. The authorization to issue shares and increase authorized capital is standard and does not indicate imminent dilution. No trading action warranted.
Key Facts
- Annual general meeting held June 2, 2026; all agenda items approved by shareholders.
- Adoption of 2025 annual accounts approved with 99.7% of votes in favor.
- Appointment of Dr. Lykke Hinsch Gylvin as non-executive director approved with 99.7% of votes.
- KPMG Accountants N.V. appointed as external auditor for fiscal year 2027 with 99.8% approval.
- Amendment of Articles of Association to increase authorized capital approved with 65.4% of votes.
- Board authorized to issue ordinary shares (64.3% approval) and to repurchase ordinary shares (66.7% approval).
- Board committees reconstituted: Audit, Compensation/Nominating/Governance, and R&D committees.
Financial Impact
No financial figures disclosed; governance items only.
Risk Factors
- Authorization to issue shares could lead to future dilution if exercised, but no current plan disclosed.
- Share repurchase authorization does not obligate the company to buy back shares.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069450 |
| Document: 0001104659-26-069450-index-headers.html | 0001104659-26-069450 |
| Document: 0001104659-26-069450-index.html | 0001104659-26-069450 |
| Document: 0001104659-26-069450.txt | 0001104659-26-069450 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
10d ago
|
6-K
| $1.47 $1.53 | ▲ +4.08% | ▲ +3.68% | $1.44 (−2.04%) |
|
May 12, 2026
4w ago
|
6-K
| $1.60 $1.70 | ▼ −6.25% | ▼ −5.67% | $1.44 (+10.00%) |
|
Apr 30, 2026
6w ago
|
6-K
| $1.57 $1.55 | ▼ −1.27% | ▼ −1.49% | $1.44 (−8.28%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $1.57 $1.55 | ▼ −1.27% | ▼ −1.49% | $1.44 (−8.28%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.98 $1.85 | ▼ −6.57% | ▼ −6.50% | $1.44 (−27.27%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $1.98 $1.85 | ▼ −6.57% | ▼ −6.50% | $1.44 (−27.27%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.83 $1.98 | ▲ +8.20% | ▲ +7.62% | $1.44 (−21.31%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $1.72 $1.82 | ▲ +5.81% | ▲ +6.41% | $1.44 (−16.28%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $1.70 $1.69 | ▼ −0.59% | ▼ −0.01% | $1.44 (−15.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access